Chromatin Bioscience

Chromatin Bioscience leverages advanced bioinformatics and multi-omics analysis to decode 'genomic dark matter' and design novel, cell-selective synthetic promoters. The company operates as a B2B technology and services provider, offering custom promoter design to enhance gene expression control for partners in therapeutics, bioproduction, and agriculture. Its flexible business model includes technology access fees and milestone payments, with clients retaining ownership of the custom-designed IP.

ChromatinLENS: A proprietary bioinformatics platform that analyzes multi-omics datasets to discover natural gene regulatory elements, enabling the design of custom, cell-type selective, and condition-responsive synthetic promoters and gene expression vectors.

Total raised: $3.5M

Chromatin faces competition from synthetic biology service providers like Twist Bioscience and Ginkgo Bioworks, as well as therapeutic platform companies developing gene regulation tools. Its differentiation lies in its focus on epigenetic data mining to create novel, patentable, cell-selective promoters and a business model where clients retain the IP for custom designs.